A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance.
Ester ConversanoHanna DebiecManuela ColucciFrancesco EmmaPierre RoncoMarina VivarelliPublished in: Pediatric nephrology (Berlin, Germany) (2023)
Obinutuzumab was safe and well-tolerated, and may therefore represent an effective therapeutic alternative in children with primary MN and rituximab resistance.